Portuguese entrepreneur selected to Forbes 30 under 30.
Bionova Capital was the first investor in Adapttech, a company that has now raised over €5M.
Lisbon, Portugal – 12 April 2021 – Bionova Capital, a leading venture capital firm investing in and building disruptive life science companies across Europe, is proud to report that Forbes has selected Frederico Carpinteiro, CEO of our portfolio company Adapttech, to its 30 under 30 European Science & Healthcare class of 2021.
Each year, Forbes identifies the world’s most promising leaders under the age of 30 across a wide range of industries, including finance, sports, entertainment, technology, science and healthcare. In this last category, Forbes recognizes leaders “inventing the future from the atom up”.
Frederico’s recognition by Forbes is the result of a very successful career as a health entrepreneur. In 2015, he co-founded Adapttech and developed the INSIGHT system, a patented medical device to make it faster and easier to correctly fit lower-limb prostheses to amputees. The INSIGHT system has now been FDA-certified and CE marked, and combines a 3D scanner, sensors, wearable technology, and a mobile app to improve prosthetic socket fitting for lower-limb amputees, and to monitor their rehabilitation process. The INSIGHT system is now globally available, following successful studies at prosthetic clinics in the USA, where the effectiveness of the INSIGHT system was independently validated.
Frederico trained as a Bioengineer at the Faculty of Engineering of the University of Porto and has been leading Adapttech since the foundation of the company. Adapttech has now raised more than €5 million from venture capital and non-dilutive grants. Bionova Capital was the first investor in Adapttech in 2016 and has since been joined by UK investors Mercia Asset Management, Angel CoFund, Wealth Club, and Wren Capital.
“I feel very honoured to receive this prestigious recognition from Forbes and want to congratulate the whole team at Adapttech”, said Frederico Carpinteiro, CEO, Adapttech. “I also thank Bionova Capital for their investment and hands-on support since the early days”.
In 2016, Bionova Capital provided the initial seed capital to Adapttech. “We were the first investors to recognize the large potential of Adapttech’s breakthrough technology. Frederico, with his strong engineering background and execution ability, was key for our investment decision”, said Peter Villax, Chairman, Bionova Capital. “Having him in Adapttech was pivotal for the success of the company, we are very proud for what he has been achieving”.
“It has been a privilege to work with Frederico, his vision and leadership allowed Adapttech to grow from Portugal to the UK and USA”, said Ricardo Perdigão Henriques, CEO, Bionova Capital. “Frederico turned Adapttech into a global company offering a unique solution to millions of amputees around the world and he will certainly inspire others to follow in his footsteps”.
Adapttech is a biomedical company focused on developing technologies that empower healthcare providers to help people with physical limitations to improve their quality of life. In 2021, Adapttech closed another €2.3 million investment round with Bionova Capital, Mercia Asset Management, Angel CoFund, Wealth Club and Wren Capital.
Frederico Carpinteiro - CEO
About Bionova Capital
Bionova Capital is a healthcare-focused venture capital firm, investing in early-stage life science companies. Founded in 2015, Bionova Capital actively manages a portfolio of six companies, three in Portugal, two in the UK, and one in Spain. Bionova Capital invests in groundbreaking therapeutics, medtech and digital health startups across Europe.
Ricardo Perdigão Henriques - CEO
Download photos and product sheets at https://www.adapttech.eu/press